Compounds > 2-anilinophenylacetic acid
Page last updated: 2024-12-09

2-anilinophenylacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-anilinophenylacetic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID854057
CHEMBL ID78188
SCHEMBL ID361662
MeSH IDM0539621

Synonyms (26)

Synonym
70172-33-7
CHEMBL78188 ,
2-(2-(phenylamino)phenyl)acetic acid
2-anilinophenylacetic acid
2-(2-anilinophenyl)acetic acid
bdbm50295277
(2-phenylamino-phenyl)-acetic acid
2-anilino-phenylacetic acid
FT-0641270
benzeneacetic acid, 2-(phenylamino)-
AM20041046
AB13923
AKOS015892915
2-[(phenyl)amino]phenylacetic acid
NJFCAWNKWPIBAG-UHFFFAOYSA-N
SCHEMBL361662
AC-26746
benzeneacetic acid,2-(phenylamino)-
DTXSID20357543
2-anilino phenylacetic acid
F52724
CS-W013007
mfcd03265448
AS-19747
A866661
2-(2-(phenylamino)phenyl)aceticacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interleukin-8Homo sapiens (human)IC50 (µMol)1.00000.00800.04360.0900AID426392
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
positive regulation of gene expressionInterleukin-8Homo sapiens (human)
negative regulation of gene expressionInterleukin-8Homo sapiens (human)
positive regulation of cellular biosynthetic processInterleukin-8Homo sapiens (human)
negative regulation of cell adhesion molecule productionInterleukin-8Homo sapiens (human)
angiogenesisInterleukin-8Homo sapiens (human)
response to molecule of bacterial originInterleukin-8Homo sapiens (human)
chemotaxisInterleukin-8Homo sapiens (human)
inflammatory responseInterleukin-8Homo sapiens (human)
signal transductionInterleukin-8Homo sapiens (human)
G protein-coupled receptor signaling pathwayInterleukin-8Homo sapiens (human)
negative regulation of cell population proliferationInterleukin-8Homo sapiens (human)
calcium-mediated signalingInterleukin-8Homo sapiens (human)
regulation of cell adhesionInterleukin-8Homo sapiens (human)
neutrophil chemotaxisInterleukin-8Homo sapiens (human)
receptor internalizationInterleukin-8Homo sapiens (human)
response to endoplasmic reticulum stressInterleukin-8Homo sapiens (human)
intracellular signal transductionInterleukin-8Homo sapiens (human)
neutrophil activationInterleukin-8Homo sapiens (human)
cellular response to fibroblast growth factor stimulusInterleukin-8Homo sapiens (human)
regulation of single stranded viral RNA replication via double stranded DNA intermediateInterleukin-8Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayInterleukin-8Homo sapiens (human)
positive regulation of angiogenesisInterleukin-8Homo sapiens (human)
embryonic digestive tract developmentInterleukin-8Homo sapiens (human)
induction of positive chemotaxisInterleukin-8Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-8Homo sapiens (human)
cellular response to interleukin-1Interleukin-8Homo sapiens (human)
cellular response to tumor necrosis factorInterleukin-8Homo sapiens (human)
positive regulation of neutrophil chemotaxisInterleukin-8Homo sapiens (human)
regulation of entry of bacterium into host cellInterleukin-8Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideInterleukin-8Homo sapiens (human)
chemokine-mediated signaling pathwayInterleukin-8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
interleukin-8 receptor bindingInterleukin-8Homo sapiens (human)
protein bindingInterleukin-8Homo sapiens (human)
chemokine activityInterleukin-8Homo sapiens (human)
heparin bindingInterleukin-8Homo sapiens (human)
CXCR chemokine receptor bindingInterleukin-8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular regionInterleukin-8Homo sapiens (human)
extracellular spaceInterleukin-8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID450463Binding affinity to D22 ssDNA aptamer2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
ssDNA aptamers that recognize diclofenac and 2-anilinophenylacetic acid.
AID450465Binding affinity to D3 ssDNA aptamer2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
ssDNA aptamers that recognize diclofenac and 2-anilinophenylacetic acid.
AID325053Inhibition of human COX2 at 4 uM for 17 mins pre-incubated before addition of [1-14C]arachidonic acid2007The Journal of biological chemistry, Jun-01, Volume: 282, Issue:22
Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
AID23265Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and quantitative structure-activity relationships of diclofenac analogues.
AID775747Inhibition of purified mouse COX-2 assessed as inhibition of PGE2-G/PGD2-G formation preincubated at 10 uM for 3 mins before 2-AG substrate addition measured after 30 seconds by LC-MS-MS method2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.
AID450464Binding affinity to D16 ssDNA aptamer2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
ssDNA aptamers that recognize diclofenac and 2-anilinophenylacetic acid.
AID325052Inhibition of mouse COX2 at 4 uM for 17 mins pre-incubated before addition of [1-14C]arachidonic acid2007The Journal of biological chemistry, Jun-01, Volume: 282, Issue:22
Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
AID160713In vitro inhibition of bovine prostaglandin G/H synthase, using bovine seminal vesicle microsomal preparations; IC50 in umol/L1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and quantitative structure-activity relationships of diclofenac analogues.
AID775746Inhibition of purified mouse COX-2 assessed as inhibition of PGE2/PGD2 formation preincubated at 10 uM for 3 mins before arachidonic acid substrate addition measured after 30 seconds by LC-MS-MS method2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.
AID426393Cytotoxicity against of human polymorphonuclear leukocytes assessed as cell viability by trypan blue dye exclusion assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
AID25584Dissociation constant (pKa)1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and quantitative structure-activity relationships of diclofenac analogues.
AID325051Inhibition of ovine COX1 at 4 uM for 17 mins pre-incubated before addition of [1-14C]arachidonic acid2007The Journal of biological chemistry, Jun-01, Volume: 282, Issue:22
Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
AID426392Inhibition of CXCL8-induced chemotaxis in human polymorphonuclear leukocyte pretreated for 15 mins measured after 4 hrs by cell migration assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
AID194137Inhibition of inflammatory hind paw edema, induced by Mycobacterium butyricum in rats; ED40 in umol/kg po1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and quantitative structure-activity relationships of diclofenac analogues.
AID426478Cytotoxicity against mouse L1.2 cells assessed as cell viability by trypan blue dye exclusion assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.79 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		8.1550amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.730aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
tolmetin
Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.		2.0510aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
ibufenac
ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.		2.0510monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		2.0710copper group element atom;
elemental silver		Escherichia coli metabolite
ibuprofen, (r)-isomer
[no description available]		2.0510ibuprofen
4'-hydroxydiclofenac
4'-hydroxydiclofenac: metabolite of diclofenac; structure in first source. 4'-hydroxydiclofenac : A monocarboxylic acid that is the 4'-hydroxylated metabolite of diclofenac.		1.9710dichlorobenzene;
monocarboxylic acid;
phenols;
secondary amino compound		allergen;
drug metabolite
cox 189
lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.		2.4620amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ketoprofen
[no description available]		2.0510
5-hydroxydiclofenac
5-hydroxydiclofenac: structure in first source. 5-hydroxydiclofenac : A monocarboxylic acid that is the 5-hydroxylated metabolite of diclofenac.		1.9710dichlorobenzene;
monocarboxylic acid;
phenols;
secondary amino compound		allergen;
drug metabolite
diclofenac sodium
Diclofenac Sodium: The sodium form of DICLOFENAC. It is used for its analgesic and anti-inflammatory properties.. diclofenac sodium : The sodium salt of diclofenac.		1.9710organic sodium salt
ConditionIndicatedRelationship StrengthStudiesTrials
Adjuvant Arthritis
[description not available]		01.9710